Daratumumab Not Cost-Effective for Multiple Myeloma
Cancer Therapy Advisor,
Adding daratumumab to standard care may improve outcomes, but it is not cost-effective for patients with untreated multiple…
Adding daratumumab to standard care may improve outcomes, but it is not cost-effective for patients with untreated multiple…
A study published in Frontiers of Pharmacology evaluated the cost-effectiveness of adding daratumumab (D) to the combination…